Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and SBRT in High-Grade Epidural Disease
NCT05204290Phase 1Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in Spinal epidural tumor, sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of Participants Completing Stereotactic Body Radiation Therapy (SBRT) and One Cycle of Pembrolizumab at Day 22. Started Mar 2022; status: terminated.
02
Drugs
03
Conditions
Spinal epidural tumor
Beyond the preview
Go deeper on NCT05204290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204290.